Canaccord lowered the firm’s price target on BioNTech (BNTX) to $158 from $171 and keeps a Buy rating on the shares. The firm said they lowered the target to reflect program discontinuations and pipeline changes over the last year. Despite declining sales, COVID remains a meaningful source of cash to fund BioNTech’s transition into a multi-product oncology company.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTX:
- BioNTech Maintained at Buy as Oncology Momentum Builds and Upside Seen at Unchanged $128 Price Target
- FDA blocked publication of studies showing Covid vaccine safe, NYT says
- BioNTech to cut up to 1,860 jobs, close multiple global sites, Reuters reports
- BioNTech Posts Wider Q1 Loss as It Doubles Down on Oncology and Plans $1 Billion Buyback
- BioNTech Posts Wider Q1 2026 Operating Loss as R&D Spend Weighs on Results